We are live on ! Find out more
AQST icon

Aquestive Therapeutics
AQST

35 hedge funds and large institutions have $17M invested in Aquestive Therapeutics in 2023 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more capital invested

Capital invested by funds: $13.6M → $17M (+$3.47M)

17% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 6

0.02% more ownership

Funds ownership: 27.56% → 27.58% (+0.02%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

5% less funds holding

Funds holding: 37 → 35 (-2)

20% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 10

Holders
35
Holders Change
-2
Holders Change %
-5.41%
% of All Funds
0.56%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
8
Increased
7
Reduced
6
Closed
10
Calls
$20K
Puts
–
Net Calls
+$20K
Net Calls Change
-$31K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$222K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$101K
3
KAS
Kestra Advisory Services
Texas
+$74.8K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$57.1K
5
Renaissance Technologies
Renaissance Technologies
New York
+$48.6K

Top Sellers

Rank Fund Capital Flow
1
SSA
Schonfeld Strategic Advisors
New York
-$457K
2
IA
IFP Advisors
Florida
-$104K
3
Man Group
Man Group
United Kingdom
-$81.1K
4
BPA
Beacon Pointe Advisors
California
-$54.1K
5
Group One Trading
Group One Trading
Illinois
-$20.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCM
1
Bratton Capital Management
Texas
$11.2M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$1.49M +$57.1K +65,854 +5%
VAFP
3
Vahanian & Associates Financial Planning
New York
$820K +$35.2K +40,650 +6%
Renaissance Technologies
4
Renaissance Technologies
New York
$591K +$48.6K +56,063 +12%
BCL
5
Bracebridge Capital LLC
Massachusetts
$489K – – –
Geode Capital Management
6
Geode Capital Management
Massachusetts
$442K – – –
BlackRock
7
BlackRock
New York
$410K +$1.68K +1,943 +0.5%
Millennium Management
8
Millennium Management
New York
$345K +$222K +256,568 +554%
LI
9
Latash Investments
Alaska
$277K – – –
BCM
10
Bridgeway Capital Management
Texas
$163K – – –
HighTower Advisors
11
HighTower Advisors
Illinois
$148K – – –
Susquehanna International Group
12
Susquehanna International Group
Pennsylvania
$133K +$101K +116,272 New
State Street
13
State Street
Massachusetts
$109K – – –
KAS
14
Kestra Advisory Services
Texas
$98.4K +$74.8K +86,350 New
Northern Trust
15
Northern Trust
Illinois
$68.2K -$1.96K -2,262 -4%
HSA
16
HBK Sorce Advisory
Pennsylvania
$48.3K +$36.7K +42,348 New
FAIM
17
Financial Advocates Investment Management
Washington
$28.5K -$6.07K -7,000 -22%
Jane Street
18
Jane Street
New York
$26.7K +$20.3K +23,430 New
Two Sigma Advisers
19
Two Sigma Advisers
New York
$26.3K -$8.06K -9,300 -29%
Bank of Montreal
20
Bank of Montreal
Ontario, Canada
$22.1K -$1.3K -1,500 -7%
Squarepoint
21
Squarepoint
New York
$17.7K +$13.5K +15,542 New
Bank of New York Mellon
22
Bank of New York Mellon
New York
$16.9K – – –
VF
23
Virtu Financial
New York
$15K +$11.2K +12,884 New
DBRC
24
D.B. Root & Company
Pennsylvania
$14.3K – – –
Wells Fargo
25
Wells Fargo
California
$13K +$3 +4 +0%
1
2

AQST Hedge Fund Activity: Q1 2023 in Review

35 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q1 2023, worth a combined $17M — up 26% from $13.6M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of AQST and 8 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 7 added.

The largest buyer was Millennium Management, adding an estimated $222K. The largest seller was Schonfeld Strategic Advisors, exiting entirely with an estimated $457K sold.

  • 35 institutional investors held Aquestive Therapeutics (AQST) as of Q1 2023, down from 37 in Q4 2022.
  • Funds reported $17M of Aquestive Therapeutics stock for Q1 2023, up 26% quarter-over-quarter.
  • 8 funds opened new Aquestive Therapeutics positions in Q1 2023 and 10 closed out, a net change of -2 holders.
  • The largest Aquestive Therapeutics buyer in Q1 2023 was Millennium Management, an estimated $222K added.
  • The largest Aquestive Therapeutics seller in Q1 2023 was Schonfeld Strategic Advisors, an estimated $457K sold.

Based on aggregated 13F filings for Q1 2023.